Illumina Inc. ($ILMN) Stock Forecast: Up 3.0% Today

What is Illumina Inc.?

Illumina (ILMN) is a leading biotechnology company specializing in genetic sequencing and array-based technologies. The company has shown strong growth and innovation in the genomics industry.

Why is Illumina Inc. going up?

ILMN stock is up 3.0% on Nov 4, 2024 15:41

• Illumina (ILMN) experienced a bullish movement today, likely driven by positive analyst projections for key metrics in its Q3 earnings.
• The long-term outperformance of Illumina in the market, with an impressive average annual return of 21.08% over the past 20 years, has also contributed to investor confidence and interest in the stock.
• The anticipation of strong performance in the quarter ended September 2024, as indicated by analyst forecasts, has further fueled bullish sentiment among investors.
• Overall, Illumina's consistent growth, market leadership in genomics, and positive earnings outlook have propelled the stock to a strong bullish movement today.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

What Analyst Projections for Key Metrics Reveal About Illumina ( ILMN ) Q3 Earnings

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

https://www.zacks.com/stock/news/2360466/what-analyst-projections-for-key-metrics-reveal-about-illumina-ilmn-q3-earnings

If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,600 Today - Illumina ( NASDAQ:ILMN )

Illumina ILMN has outperformed the market over the past 20 years by 12.72% on an annualized basis producing an average annual return of 21.08%. Currently, Illumina has a market capitalization of $22.90 billion.

https://www.benzinga.com/insights/news/24/10/41582659/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-4-600-today

Trending Today

Sui ($SUI) Crypto Forecast: Up 5.5% Today

Fetch.ai ($FET) Crypto Forecast: Up 5.4% Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 8.4% Today

THORChain ($RUNE) Crypto Forecast: Down 9.6% Today

Bonk ($BONK) Crypto Forecast: Up 5.1% Today

Toncoin ($TON) Crypto Forecast: Down 5.0% Today

Celestia ($TIA) Crypto Forecast: Down 6.1% Today

Natural Gas ($GAS) Commodity Forecast: Up 5.3% Today

Pendle ($PENDLE) Crypto Forecast: Down 7.2% Today

Illumina Inc. Price History

13.08.2024 - ILMN Stock was up 6.1%

• Illumina (ILMN) exhibited a notable bullish trend today, likely influenced by:
• Recognition of the stock's impressive long-term performance, drawing in investors seeking stable returns.
• Mention of a recent earnings surge, potentially boosting confidence in the company's growth outlook and attracting more buyers.
• Positive market sentiment towards Illumina's innovative technologies and the promising opportunities within the biotech industry.

02.09.2024 - ILMN Stock was up 5.8%

• Illumina's significant surge in the market today can be linked to its remarkable long-term performance, averaging a 20.33% annual return over the last two decades.
• Investor confidence in Illumina's future within the biotechnology industry may be fueling the increased demand for its stock.
• The company's market capitalization of $20.38 billion highlights investors' trust in its innovative technologies and potential for further expansion.
• Taken together, Illumina's consistent market outperformance and ongoing advancements in genetic sequencing likely played a role in today's positive market movement.

04.10.2024 - ILMN Stock was up 3.0%

• Illumina (ILMN) experienced a bullish movement today, likely driven by positive analyst projections for key metrics in its Q3 earnings.
• The long-term outperformance of Illumina in the market, with an impressive average annual return of 21.08% over the past 20 years, has also contributed to investor confidence and interest in the stock.
• The anticipation of strong performance in the quarter ended September 2024, as indicated by analyst forecasts, has further fueled bullish sentiment among investors.
• Overall, Illumina's consistent growth, market leadership in genomics, and positive earnings outlook have propelled the stock to a strong bullish movement today.

16.06.2024 - ILMN Stock was up 5.1%

• The acquisition of Fluent Biosciences by Illumina adds single-cell analysis technology to its portfolio.
• Illumina has strategically expanded its reach in single-cell analysis and multiomics research through acquisitions, positively impacting investor sentiment.
• The bullish market movement may be influenced by the positive performance of the biotech sector, with companies like Nvidia leading the Nasdaq and S&P 500 to record high closes.
• The slipping of 10x Genomics stock as Illumina acquires a competitor might have further boosted confidence in Illumina's growth prospects and market position.

16.06.2024 - ILMN Stock was up 6.2%

• The uptick in Illumina's stock value may be linked to the imminent release of its second-quarter financial results, causing optimistic reactions from investors who anticipate a robust performance.
• The recent acquisition of Fluent Biosciences, which enhances its range with single-cell analysis technology, likely played a role in the stock's upsurge, showcasing strategic expansion and product diversification.
• The general positive market atmosphere, marked by new highs in Nasdaq and S&P 500 indices, probably additionally supported Illumina's stock, especially considering favorable remarks on potential rate adjustments by Powell and the sound showings of tech peers like Nvidia and Apple.

07.07.2024 - ILMN Stock was up 5.4%

• Better-than-expected second-quarter sales results were reported by Illumina, leading to an increase in analyst forecasts and a bullish movement in the stock.
• Citigroup raised Illumina's stock target and maintained a positive rating due to strong margins, further boosting investor confidence.
• Despite a revenue decline amid market challenges, Illumina managed to improve its margins, which was well-received by investors and contributed to the bullish movement in the stock.
• The positive earnings report and analyst upgrades likely fueled investor optimism and drove the stock higher throughout the trading day.

07.07.2024 - ILMN Stock was up 8.0%

• The bullish movement in Illumina's stock today is attributed to positive news and performance indicators:
• Citigroup raised the stock target and maintained a strong rating based on robust margins.
• Despite market challenges, the company improved its margins, which is likely viewed positively by investors.
• Illumina's Q2 earnings and revenues surpassed estimates significantly, indicating strong financial performance.
• The reported loss in the second quarter might have been overshadowed by the positive aspects of improved margins and exceeding earnings expectations, leading to the bullish market movement.

13.07.2024 - ILMN Stock was down 5.2%

• Illumina reported surpassing Q2 earnings expectations, although it adjusted its 2024 sales forecast downwards, reflecting difficulties within the global macroeconomic landscape.
• Anticipating a decrease in yearly sales within its primary segment due to constraints in biotech funding, Illumina's future outlook is affected.
• Despite the negative stock movement, analysts have raised their price target for Illumina, showcasing faith in the company's potential longevity.
• The downward movement in Illumina's stock is possibly linked to a blend of factors including the mixed earnings report, revised sales forecast, and uncertainties surrounding future demand in the gene sequencing industry amidst biotech funding challenges.

05.07.2024 - ILMN Stock was up 5.3%

• The stock of Illumina experienced a significant bullish movement recently.
• The company's launch of a new oncology menu for NovaSeq X Series customers indicates a focus on expanding its oncology testing capabilities, which might have influenced positive investor sentiment.
• Market anticipation of Illumina outperforming earnings estimates for the quarter ended June 2024 likely supported the bullish trend, reflecting investor confidence in the company's financial performance.
• Negative sentiment expressed towards Illumina on a financial program might have initially caused some uncertainty, but the overall market response has been largely positive, possibly driven by advancements in Illumina's product offerings and financial outlook.

08.07.2024 - ILMN Stock was up 5.6%

• Illumina's shares surged as analysts increased their price targets post strong Q2 results, indicating confidence in the company's performance and growth potential.
• The decision to raise Illumina's stock target, coupled with a maintained strong rating from Citi, underscores a positive view on the company's profitability and margins.
• Despite a revenue dip due to market challenges, Illumina enhanced its margins, demonstrating resilience and effective cost management.
• The upward trend in Illumina's stock value can be attributed to improved financial performance, optimistic analyst predictions, and overall market positivity propelling the stock upwards.

14.07.2024 - ILMN Stock was up 5.6%

• Illumina, Inc. received a reaffirmation of a "Buy" rating, with new product launches boosting the growth outlook, which likely contributed to the bullish movement.
• Despite beating Q2 earnings expectations, Illumina lowered its 2024 sales view, indicating potential concerns about future performance.
• Activist pressure could be driving some market excitement and speculation around potential strategic changes within the company.
• The overall positive sentiment around gene editing stocks and the potential for transformative medicine may have also positively influenced Illumina's stock performance today.

15.07.2024 - ILMN Stock was up 5.1%

• Illumina's solid performance over the past 20 years, with an annualized return of 21.21%, likely contributed to the bullish movement today.
• The reaffirmation of a "Buy" rating by a prominent analyst, citing new product launches boosting growth outlook, could have instilled confidence in investors and further fueled the positive momentum.
• Despite surpassing Q2 earnings expectations, the update on lowering 2024 sales view might have initially caused some concerns but was overshadowed by the overall positive sentiment towards the company.
• The activist pressure from Icahn Enterprises may have initially raised some uncertainties, but the market seemed to focus more on the company's long-term growth potential and resilience.